TY - JOUR
T1 - Risks, diagnosis, and management of recurrent cancer-associated thrombosis (CAT)
T2 - a narrative review
AU - Dickson, Kodwo
AU - Koom-Dadzie, Kwame
AU - Brito-Dellan, Norman
AU - Escalante, Carmen
N1 - Funding Information:
The manuscript was edited by Sarah Bronson, ELS, of the Research Medical Library at The University of Texas MD Anderson Cancer Center.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/10
Y1 - 2022/10
N2 - This paper aims to provide a narrative review of the risks, diagnosis, and management of recurrent venous thromboembolism (VTE) in cancer patients. There is an established association between cancer and VTE, with cancer being a major risk factor for VTE. A history of VTE, short duration of oral anticoagulation, and a proximal DVT are all associated with increased risk for recurrent VTE. Studies have shown that certain cancers (e.g., metastatic genitourinary, lung, and colorectal cancers) are associated with recurrent VTE. Published literature shows that cancer is prothrombotic, and various mechanisms have been postulated as pathways for increased thrombogenesis and hence recurrent VTE in cancer. The symptoms, signs, laboratory information, and imaging results for the diagnosis of recurrent VTE are similar to those of an initial VTE. Management of recurrent VTE involves using low molecular weight heparin (LMWH) or a direct oral anticoagulant (DOAC). Vitamin K antagonists (VKA) or inferior vena cava (IVC) filters are less commonly used.
AB - This paper aims to provide a narrative review of the risks, diagnosis, and management of recurrent venous thromboembolism (VTE) in cancer patients. There is an established association between cancer and VTE, with cancer being a major risk factor for VTE. A history of VTE, short duration of oral anticoagulation, and a proximal DVT are all associated with increased risk for recurrent VTE. Studies have shown that certain cancers (e.g., metastatic genitourinary, lung, and colorectal cancers) are associated with recurrent VTE. Published literature shows that cancer is prothrombotic, and various mechanisms have been postulated as pathways for increased thrombogenesis and hence recurrent VTE in cancer. The symptoms, signs, laboratory information, and imaging results for the diagnosis of recurrent VTE are similar to those of an initial VTE. Management of recurrent VTE involves using low molecular weight heparin (LMWH) or a direct oral anticoagulant (DOAC). Vitamin K antagonists (VKA) or inferior vena cava (IVC) filters are less commonly used.
KW - Cancer
KW - Cancer-associated thrombosis
KW - Direct oral anticoagulants
KW - Low molecular weight heparin
KW - Recurrent venous thromboembolism
KW - Vitamin K antagonist
UR - http://www.scopus.com/inward/record.url?scp=85131819049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131819049&partnerID=8YFLogxK
U2 - 10.1007/s00520-022-07160-w
DO - 10.1007/s00520-022-07160-w
M3 - Article
C2 - 35699781
AN - SCOPUS:85131819049
SN - 0941-4355
VL - 30
SP - 8539
EP - 8545
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 10
ER -